Search
Stories, the companies and people Loro tracks, and the primary records behind them — filings, donations, contracts and disclosures.
Company or person4
Kairos Pharma, LTD.
Company
Nasus Pharma Ltd
Company
UroGen Pharma Ltd.
Company
Medicus Pharma Ltd.
Company
Primary record5
Kairos Pharma, LTD. filed 8-K
Item 8.01. Other Events. On November 5, 2026, Kairos Pharma, Ltd. (the “Company”) issued a press release announcing that the Company has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Canc
Kairos Pharma, LTD. filed 8-K
Item 1.01 Entry into a Material Definitive Agreement. Amendments to Purchase Agreement As previously disclosed in the Company’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November
Kairos Pharma, LTD. filed 8-K
Item 8.01. Other Events. On October 6, 2026, Kairos Pharma, Ltd. (the Company ) issued a press release reporting interim efficacy data from the Company s ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in
Kairos Pharma, LTD. filed 8-K
Item 7.01. Regulation FD Disclosure. On September 14, 2026, Kairos Pharma, Ltd., a Delaware corporation (the Company ), issued a new investor presentation, which will be published on the Company s website, www.kairosphar
Kairos Pharma, LTD. filed 8-K
Item 3.03 Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information regarding the Reverse Stock Split (as defined below) contained in Item 5.03 of this Current